A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as
combination therapy in subjects with advanced solid tumor malignancies.